Protagonist Therapeutics, Inc PTGX
- PN-477 — Obesity Phase 1
- PN-458 — Obesity Preclinical
- PN-458 — Obesity Preclinical
GLP-1R (4 companies · 8 programs)
Companies with an active program directed at GLP-1R.
Structure Therapeutics Inc. GPCR
- aleniglipron — Obesity Phase 3
- aleniglipron — Type 2 Diabetes Phase 3
Viking Therapeutics, Inc. VKTX
- VK2735 — Obesity Phase 3
- VK2735 — Obesity Phase 2
Coya Therapeutics, Inc. COYA
- COYA 303 Preclinical